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260.000 atherosclerosis-related hospitalizations occurred
in Italy. There is evidence that Amlodipine treatment is
effective in reducing the health burden of atherosclerosis
and the objective of this analysis is to assess the pharma-
coeconomic proﬁle of Amlodipine in atherosclerotic
disease and in the Italian scenario. METHODS: Alterna-
tives: standard care plus Amlodipine besylate treatment
vs standard care alone in patients with CAD identiﬁed by
angiography in Italy. Perspective: National Health Service
(NHS). Technique: cost-effectiveness analysis on 2 hypo-
thetical cohorts of 1000 subjects; an incremental cost 
per patient free for events has been calculated. Time: 36
months. All effects and costs were discounted with an
annual rate of 5%. Costs: drugs and direct medical costs
quantiﬁed by using NHS tariffs expressed in €2002.
Effects: measured through the results from the PREVENT
study (Pitt B et al, 2000): i.e. fatal acute myocardial
infarction (AMI) or not, fatal stroke or not, congestive
heart failure, unstable angina, CABG and PTCA.
RESULTS: Treating the hypotethical cohort of 1000 sub-
jects with Amlodipine resulted in a total cost of
€2,896,345 (€1,267,472 for pharmacological treatment
and €1,628,873 for treating 355 events). Treating the
hypotethical cohort of 1000 subjects with placebo
resulted in a total cost of €2,643,732 to follow 547
events. The treatment with Amlodipine was superior
regarding the development of any ﬁrst event (206 with
Amlodipine and 284 with placebo) and the incremental
cost per patient free for events was €3,235. CONCLU-
SIONS: The results indicate that Amlodipine therapy is
more effective and more costly than placebo and that a
drug investment with Amlodipine leads to a signiﬁcant
reduction of the health burden of atherosclerotic disease.
The incremental health beneﬁt can be obtained at an
affordable cost.
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OBJECTIVE: The AVERT study (Atorvastatin versus
Revascularization Treatment) showed the beneﬁts of the
aggressive treatment with Atorvastin (ATV) 80mg/day in
reducing the incidence of ischemic events. The objective
of this analysis was to compare the associated costs of
ATV-80mg vs Percutaneous Coronary Intervention (PCI)
using unit costs from Spain. METHODS: This Econom-
ical Evaluation (EE) compared the total expected cost and
cost-effectiveness of treatment with ATV-80mg daily
versus PCI, for 18 months. 341 patients (pts) with stable
coronary artery disease were randomized to receive
medical treatment with ATV-80mg/day (164pts), or 
to undergo the recommended PCI followed by usual 
care including lipid-lowering treatments (177pts). The
primary outcome was ischemic cardiovascular events. 
EE has been performed from a 3rd payer perspective (the
National Health Services, with 2001 costs). The cost of
ATV-80mg used was twice ATV-40mg (€2.64 per tablet)
currently marketed. RESULTS: The 164pts included in
ATV-group suffered 36 events (22pts) with hospitaliza-
tion and the 177pts in PCI-group, 61 events (37pts). The
Total Cost in ATV-group was €378,853.31: sum of Ator-
vastatin-80mg Treatment Total Cost: 233,798,40€and all
Inpatient Events Cost: €145,054.91 (in this amount is
included 18 PCIs as event: €76,676.40). The Total Cost
in PCI-group was €1,075,647.82: sum of PCI Total Cost:
€753,984.60, all Inpatient Events Cost €280,504.42
(included 21 PCIs as event in this group: €89,455.80),
and Concomitant Lipid-lowering Treatment Cost:
€41,158.80. Therefore the Cost Per Event in ATV-group
was €2,310.08 and 6,077.11€ in PCI-group, with a dif-
ference of €3,767.03 per event more in the PCI-group.
The Incremental Cost Per Event Avoided was 
-€30,107.16 in the ATV-group. CONCLUSIONS: In
low-risk patients with stable coronary artery disease,
aggressive lipid-lowering therapy with ATV-80mg/day is
at least as effective as angioplasty, after 18 months of
follow-up, and it is cost-saving to the National Health
Services.
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OBJECTIVE: To compare the economic consequences of
antihypertensive treatment with perindopril (1 ¥ 4mg)
and enalapril (2 ¥ 10mg). METHODS: The clinical, epi-
demiological and economic data were derived from a sci-
entiﬁc project conducted in the whole of Poland among
GPs, and concerned 438 patients treated in mono-therapy
within the last year. Calculations were made from the
societal perspective and the retrospective approach was
applied. The direct medical costs of: pharmacological
treatment, doctors’ consultations, hospitalisation, labora-
tory and diagnostic tests were identiﬁed and calculated.
Indirect costs were also assessed by the capital cost
method. Effectiveness was measured by the percentage of
the patients with appropriate blood pressure control
according to the ﬁrst deﬁnition (BP£140/90mmHg) and
the second deﬁnition, (BP < 140/90mmHg), consistent
with JNC VI guidelines. RESULTS: Effectiveness, mea-
sured according to the ﬁrst deﬁnition was 52,45% in the
perindopril group and 41,03% in the enalapril group.
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According to the second deﬁnition it was respectively,
43,63% and 25,64%. Cost of the doctors’ consultations
in the perindopril group was lower by 16,52% than in
the enalapril group, which represents a saving of €19,29
per patient per year. Indirect costs reduction in the
perindopril group amounted to €131,26 per patient per
year which means -54,06%. Total cost in the perindopril
group, was lower by €55,44 per patient per year than in
the enalapril group. Calculation of the cost-effectiveness
ratios according to the ﬁrst deﬁnition (Wp = 1020; WE =
1439) and the second deﬁnition (Wp = 1226; WE = 2303)
revealed the treatment with perindopril as a more cost-
effective than enalapril. CONCLUSION: The results of
the analysis revealed signiﬁcant cost reductions and better
blood pressure control in the perindopril group as com-
pared to the enalapril group. The savings in the perindo-
pril group resulted from the reduction of the physicians’
consultation costs and from the considerable reduction of
the indirect costs.
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OBJECTIVES: Two models of ambulatory oral anticoag-
ulation management have been adopted in a teaching hos-
pital in Hong Kong, namely the anticoagulation clinic
(AC) and routine medical care (RMC). The objective of
this study was to compare the cost and outcomes of war-
farin therapy management at AC and RMC from the per-
spective of a public health organization. METHODS:
A retrospective observational study was performed by
reviewing the medical records of outpatients who were
initiated on warfarin from January 1, 1999 to June 30,
2001 in a teaching hospital. Effectiveness was assessed by
percentage of patient-time spent in target INR range and
the incidence of thromboembolic events (TE). Safety was
assessed by incidence of hemorrhage and warfarin over-
dose (INR > 5). Direct medical cost associated with the
management of warfarin therapy and anticoagulation
complications was also evaluated. The incidences were
expressed as percentage per patient-year. RESULTS:
Forty-one patients (71 patient-years) and 476 patients
(409 patient-years) were started on warfarin in AC and
RMC, respectively, during the study period. Patients
managed by AC spent signiﬁcantly more time in target
INR range than those in RMC group (58% vs. 44%; p =
0.002) and had a lower incidence of INR > 5 (1.4% vs.
7.1%; p = 0.068). The AC group patients had a lower
rate of TE (4.2% vs. 7.6%; p = 0.443) and major to fatal
bleeding (0% vs. 9.5%; p = 0.01). The total direct medical
cost of AC was lower than that of RMC by 44%
(HKD4838 vs. HKD8595 per patient year; 1USD =
7.8HKD). CONCLUSION: The establishment of the AC
improved the effectiveness, safety, and decreased the
direct medical cost of oral anticoagulation therapy.
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OBJECTIVES: Cardiovascular diseases (CVD) are one of
the leading causes of morbidity and mortality in Italy.
Atorvastatin treatment has shown to be effective in con-
trolling cholesterol levels in hyperlipidemic subjects.
Scope of this analysis is to evaluate the pharmacoeco-
nomic proﬁle of Atorvastatin compared to other statins
in subjects with a global CVD yearly risk >2%.
METHODS: Alternatives: Atorvastatin (low dose) vs
other statins (low dose) on the Italian market (weighted
with the current market shares, Atorvastatin excluded).
Perspective: National Health Service (NHS). Technique:
cost-effectiveness analysis on 2 hypothetical cohorts of
1000 subjects in primary prevention, with a global CVD
yearly risk >2%; an incremental cost per life year gained
(LYG) has been calculated. Time: 5 years. Costs: drugs
and direct medical costs quantiﬁed by using NHS tariffs
expressed in Euro 2002. Effects: the effects of different
statins in controlling cholesterol levels, as measured with
the CURVES study (Jones P et al, Am J Cardiol 1998),
have been used to model mortality and morbidity from
CVD with the Framingham Risk Equations (Anderson
KM et al, Am Heart J 1990). RESULTS: In the Atorvas-
tatin group the cost of drug therapy and events was
€2.213.415 for 58 LYG, resulting in an incremental cost
per LYG of €38.178. With other statins the cost of drug
therapy and events was €2.569.512 for 49 LYG, result-
ing in an incremental cost per LYG of €52.933. The 
differences always favoured the subjects treated with
Atorvastatin. CONCLUSIONS: This economic evalua-
tion shows that Atorvastatin is dominant over the treat-
ment with other statins as currently prescribed, as it
allows a higher number of LYG and is less costly.
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OBJECTIVE: A recent randomized clinical trial demon-
strated that improvement in moderate to severe conges-
tive heart failure (CHF) with treatment for anemia. To
estimate the health economic implications of treating
anemia with subcutaneous erythropoietin and intra-
venous iron in patients with moderate to severe CHF.
METHODS: A Markov model of CHF was developed
using New York Heart Association (NYHA) classes as the
main states and the effects of anemia treatment on these.
